Cargando…
Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is the leading indication of liver transplantation (LT) among autoimmune liver disease patients. There is a scarcity of studies comparing survival outcomes between living-donor liver transplants (LDLT)s and deceased-donor liver transplants (DDLTs) in this populat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145248/ https://www.ncbi.nlm.nih.gov/pubmed/37109144 http://dx.doi.org/10.3390/jcm12082807 |
_version_ | 1785034287593029632 |
---|---|
author | Sierra, Leandro Barba, Romelia Ferrigno, Bryan Goyes, Daniela Diaz, Wilfor Patwardhan, Vilas R. Saberi, Behnam Bonder, Alan |
author_facet | Sierra, Leandro Barba, Romelia Ferrigno, Bryan Goyes, Daniela Diaz, Wilfor Patwardhan, Vilas R. Saberi, Behnam Bonder, Alan |
author_sort | Sierra, Leandro |
collection | PubMed |
description | Primary sclerosing cholangitis (PSC) is the leading indication of liver transplantation (LT) among autoimmune liver disease patients. There is a scarcity of studies comparing survival outcomes between living-donor liver transplants (LDLT)s and deceased-donor liver transplants (DDLTs) in this population. Using the United Network for Organ Sharing database, we compared 4679 DDLTs and 805 LDLTs. Our outcome of interest was post-LT patient survival and post-LT graft survival. A stepwise multivariate analysis was performed, adjusting for recipient age, gender, diabetes mellitus, ascites, hepatic encephalopathy, cholangiocarcinoma, hepatocellular carcinoma, race, and the model for end-stage liver disease (MELD) score; donor’ age and sex were also included to the analysis. According to univariate and multivariate analysis, LDLT had a patient and graft survival benefit compared to DDLT (HR, 0.77, 95% CI 0.65–0.92; p < 0.002). LDLT patient survival (95.2%, 92.6%, 90.1%, and 81.9%) and graft survival (94.1%, 91.1%, 88.5%, and 80.5%) at 1, 3, 5, and 10 years were significantly better than DDLT patient survival (93.2%, 87.6%, 83.3%, and 72.7%) and graft survival (92.1%, 86.5%, 82.1%, and 70.9%) (p < 0.001) in the same interval. Variables including donor and recipient age, male recipient gender, MELD score, diabetes mellitus, hepatocellular carcinoma, and cholangiocarcinoma were associated with mortality and graft failure in PSC patients. Interestingly, Asians were more protected than Whites (HR, 0.61; 95% CI, 0.35–0.99; p < 0.047), and cholangiocarcinoma was associated with the highest hazard of mortality (HR, 2.07; 95% CI, 1.71–2.50; p < 0.001) in multivariate analysis. LDLT in PSC patients were associated with greater post-transplant patient and graft survival compared to DDLT patients. |
format | Online Article Text |
id | pubmed-10145248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101452482023-04-29 Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis Sierra, Leandro Barba, Romelia Ferrigno, Bryan Goyes, Daniela Diaz, Wilfor Patwardhan, Vilas R. Saberi, Behnam Bonder, Alan J Clin Med Article Primary sclerosing cholangitis (PSC) is the leading indication of liver transplantation (LT) among autoimmune liver disease patients. There is a scarcity of studies comparing survival outcomes between living-donor liver transplants (LDLT)s and deceased-donor liver transplants (DDLTs) in this population. Using the United Network for Organ Sharing database, we compared 4679 DDLTs and 805 LDLTs. Our outcome of interest was post-LT patient survival and post-LT graft survival. A stepwise multivariate analysis was performed, adjusting for recipient age, gender, diabetes mellitus, ascites, hepatic encephalopathy, cholangiocarcinoma, hepatocellular carcinoma, race, and the model for end-stage liver disease (MELD) score; donor’ age and sex were also included to the analysis. According to univariate and multivariate analysis, LDLT had a patient and graft survival benefit compared to DDLT (HR, 0.77, 95% CI 0.65–0.92; p < 0.002). LDLT patient survival (95.2%, 92.6%, 90.1%, and 81.9%) and graft survival (94.1%, 91.1%, 88.5%, and 80.5%) at 1, 3, 5, and 10 years were significantly better than DDLT patient survival (93.2%, 87.6%, 83.3%, and 72.7%) and graft survival (92.1%, 86.5%, 82.1%, and 70.9%) (p < 0.001) in the same interval. Variables including donor and recipient age, male recipient gender, MELD score, diabetes mellitus, hepatocellular carcinoma, and cholangiocarcinoma were associated with mortality and graft failure in PSC patients. Interestingly, Asians were more protected than Whites (HR, 0.61; 95% CI, 0.35–0.99; p < 0.047), and cholangiocarcinoma was associated with the highest hazard of mortality (HR, 2.07; 95% CI, 1.71–2.50; p < 0.001) in multivariate analysis. LDLT in PSC patients were associated with greater post-transplant patient and graft survival compared to DDLT patients. MDPI 2023-04-11 /pmc/articles/PMC10145248/ /pubmed/37109144 http://dx.doi.org/10.3390/jcm12082807 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sierra, Leandro Barba, Romelia Ferrigno, Bryan Goyes, Daniela Diaz, Wilfor Patwardhan, Vilas R. Saberi, Behnam Bonder, Alan Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis |
title | Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis |
title_full | Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis |
title_fullStr | Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis |
title_full_unstemmed | Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis |
title_short | Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis |
title_sort | living-donor liver transplant and improved post-transplant survival in patients with primary sclerosing cholangitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145248/ https://www.ncbi.nlm.nih.gov/pubmed/37109144 http://dx.doi.org/10.3390/jcm12082807 |
work_keys_str_mv | AT sierraleandro livingdonorlivertransplantandimprovedposttransplantsurvivalinpatientswithprimarysclerosingcholangitis AT barbaromelia livingdonorlivertransplantandimprovedposttransplantsurvivalinpatientswithprimarysclerosingcholangitis AT ferrignobryan livingdonorlivertransplantandimprovedposttransplantsurvivalinpatientswithprimarysclerosingcholangitis AT goyesdaniela livingdonorlivertransplantandimprovedposttransplantsurvivalinpatientswithprimarysclerosingcholangitis AT diazwilfor livingdonorlivertransplantandimprovedposttransplantsurvivalinpatientswithprimarysclerosingcholangitis AT patwardhanvilasr livingdonorlivertransplantandimprovedposttransplantsurvivalinpatientswithprimarysclerosingcholangitis AT saberibehnam livingdonorlivertransplantandimprovedposttransplantsurvivalinpatientswithprimarysclerosingcholangitis AT bonderalan livingdonorlivertransplantandimprovedposttransplantsurvivalinpatientswithprimarysclerosingcholangitis |